Neurogene Inc.
NGNEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Neurogene Inc. focuses on Biotechnology services and products. Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. With a market capitalization of $471.3M, it sits in small-cap territory. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Market Cap
$471.3M
Beta
2.09
P/E (TTM)
—
P/E (Fwd)
-4.11
EPS (TTM)
$-5.04
EPS (Fwd)
$-5.72
ROE
-45.3%
ROA
-28.0%
Cash
$225.4M
Total Debt
$8.3M
Free CF
-$48.1M
52W Change
-26.5%
Annual Financials
Cash vs Debt
Where NGNE stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, NGNE finished 26.51% below its 150-day moving average ($30.18) and 19.11% below its 200-day moving average ($27.42). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NGNE overbought or oversold?
At the October 15, 2026 close, NGNE's RSI(14) was 18.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Neurogene Inc. holds $225.4M in cash against $8.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$48.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -45.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta above 1.5, NGNE tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, NGNE has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing NGNE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.